WO2011049948A3 - Neuroprotection et réparation de la myéline au moyen de la nestorone® - Google Patents

Neuroprotection et réparation de la myéline au moyen de la nestorone® Download PDF

Info

Publication number
WO2011049948A3
WO2011049948A3 PCT/US2010/053201 US2010053201W WO2011049948A3 WO 2011049948 A3 WO2011049948 A3 WO 2011049948A3 US 2010053201 W US2010053201 W US 2010053201W WO 2011049948 A3 WO2011049948 A3 WO 2011049948A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegeneration
compound
myelin repair
treating
nestorone
Prior art date
Application number
PCT/US2010/053201
Other languages
English (en)
Other versions
WO2011049948A2 (fr
WO2011049948A4 (fr
Inventor
Regine Sitruk-Ware
Michael Maria Helmut Schumacher
Roberta Brinton
Martine El-Etr
Abdelmouman Ghoumari
Rachida Guennoun
Original Assignee
The Population Council, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112012009306A priority Critical patent/BR112012009306A2/pt
Priority to MX2012004542A priority patent/MX347890B/es
Priority to CA2777551A priority patent/CA2777551C/fr
Priority to ES10768168.6T priority patent/ES2669694T3/es
Priority to AU2010308308A priority patent/AU2010308308B2/en
Priority to JP2012535303A priority patent/JP5871807B2/ja
Application filed by The Population Council, Inc. filed Critical The Population Council, Inc.
Priority to EP10768168.6A priority patent/EP2490680B1/fr
Priority to US13/500,008 priority patent/US10052335B2/en
Publication of WO2011049948A2 publication Critical patent/WO2011049948A2/fr
Publication of WO2011049948A3 publication Critical patent/WO2011049948A3/fr
Publication of WO2011049948A4 publication Critical patent/WO2011049948A4/fr
Priority to US13/725,064 priority patent/US9446051B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a pour objet des méthodes de traitement de la neurodégénérescence et/ou de la myélinisation chez des patients, comprenant le traitement du patient au moyen d'un composé progestatif qui exerce une liaison aux récepteurs de la progestérone et provoque des réponses biologiques induites par les récepteurs de la progestérone sans interagir avec le récepteur des androgènes et sans induire de réponses biologiques des androgènes ou des glucocorticoïdes à un dosage suffisant pour prévenir ou réduire la neurodégénérescence. Le composé progestatif comprend de préférence de la 16-méthylène-17α-acétoxy-19-norpregn-4-ène-3, 20- dione, et les méthodes comprennent l'association du composé progestatif avec un composé œstrogène pour fournir à la fois une contraception et un traitement pour la réparation de la myéline et la neurodégénérescence.
PCT/US2010/053201 2009-10-19 2010-10-19 Neuroprotection et réparation de la myéline au moyen de la nestorone® WO2011049948A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2012004542A MX347890B (es) 2009-10-19 2010-10-19 Neuroproteccion y reparacion de melina usando progestina.
CA2777551A CA2777551C (fr) 2009-10-19 2010-10-19 Neuroprotection et reparation de la myeline au moyen de la nestorone
ES10768168.6T ES2669694T3 (es) 2009-10-19 2010-10-19 Neuroprotección y reparación de mielina usando Nestorone®
AU2010308308A AU2010308308B2 (en) 2009-10-19 2010-10-19 Neuroprotection and myelin repair using nestorone®
JP2012535303A JP5871807B2 (ja) 2009-10-19 2010-10-19 ネストロン（ｎｅｓｔｏｒｏｎｅ（登録商標））を使用する神経保護およびミエリン修復
BR112012009306A BR112012009306A2 (pt) 2009-10-19 2010-10-19 método para regeneração de mielina em um paciente
EP10768168.6A EP2490680B1 (fr) 2009-10-19 2010-10-19 Neuroprotection et réparation de la myéline au moyen de la nestorone®
US13/500,008 US10052335B2 (en) 2009-10-19 2010-10-19 Neuroprotection and myelin repair using Nestorone®
US13/725,064 US9446051B2 (en) 2009-10-19 2012-12-21 Neuroprotection and myelin repair using nestorone®

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932009P 2009-10-19 2009-10-19
US61/279,320 2009-10-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/500,008 A-371-Of-International US10052335B2 (en) 2009-10-19 2010-10-19 Neuroprotection and myelin repair using Nestorone®
US13/725,064 Continuation-In-Part US9446051B2 (en) 2009-10-19 2012-12-21 Neuroprotection and myelin repair using nestorone®

Publications (3)

Publication Number Publication Date
WO2011049948A2 WO2011049948A2 (fr) 2011-04-28
WO2011049948A3 true WO2011049948A3 (fr) 2011-06-16
WO2011049948A4 WO2011049948A4 (fr) 2011-08-04

Family

ID=43413545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053201 WO2011049948A2 (fr) 2009-10-19 2010-10-19 Neuroprotection et réparation de la myéline au moyen de la nestorone®

Country Status (9)

Country Link
US (1) US10052335B2 (fr)
EP (1) EP2490680B1 (fr)
JP (1) JP5871807B2 (fr)
AU (1) AU2010308308B2 (fr)
BR (1) BR112012009306A2 (fr)
CA (1) CA2777551C (fr)
ES (1) ES2669694T3 (fr)
MX (1) MX347890B (fr)
WO (1) WO2011049948A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052335B2 (en) 2009-10-19 2018-08-21 The Population Council, Inc. Neuroprotection and myelin repair using Nestorone®
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
IN2012DN04867A (fr) 2009-12-17 2015-09-25 Population Council Inc
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2688571A1 (fr) 2011-03-22 2014-01-29 The Population Council, Inc. Rénégération de myéline par des androgènes
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (fr) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
CN102688247A (zh) * 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US9808470B2 (en) * 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2836388A1 (fr) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection et reparation de la myeline a l'aide de st-1435
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015088625A2 (fr) 2013-09-25 2015-06-18 Case Western Reserve University Composés et procédés pour favoriser la myélinisation
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
WO2016005599A1 (fr) * 2014-07-10 2016-01-14 Biocopea Limited Compositions, procédés et utilisations pour le traitement de troubles immunitaires dépendant du sexe
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097071A1 (fr) * 2002-05-17 2003-11-27 Wyeth Hormonotherapie substitutive utilisant une combinaison d'oestrogenes conjugues et de trimegestone
US20060205704A1 (en) * 2005-03-04 2006-09-14 Alsgen, Llc Modulation of neurodegenerative diseases through the progesterone receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4760092A (en) * 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US7037332B2 (en) 2000-03-15 2006-05-02 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence
US6891081B1 (en) 2000-08-14 2005-05-10 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
ES2278925T3 (es) 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
AU2002365513A1 (en) * 2001-11-30 2003-06-10 Solvay Pharmaceuticals Gmbh Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
US20040087563A1 (en) 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
EP2164498A4 (fr) * 2007-06-04 2010-09-08 Univ California Association d'hormone de grossesse pour le traitement de maladies autoimmunes
US10052335B2 (en) 2009-10-19 2018-08-21 The Population Council, Inc. Neuroprotection and myelin repair using Nestorone®
CN102688247A (zh) 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途
CN102657661A (zh) 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097071A1 (fr) * 2002-05-17 2003-11-27 Wyeth Hormonotherapie substitutive utilisant une combinaison d'oestrogenes conjugues et de trimegestone
US20060205704A1 (en) * 2005-03-04 2006-09-14 Alsgen, Llc Modulation of neurodegenerative diseases through the progesterone receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LENZI E ET AL: "Central modifications of allopregnanolone and beta-endorphin following subcutaneous administration of Nestorone", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 116, no. 1-2, 1 August 2009 (2009-08-01), pages 15 - 20, XP026211788, ISSN: 0960-0760, [retrieved on 20090419], DOI: DOI:10.1016/J.JSBMB.2009.04.004 *
SCHUMACHER M ET AL: "Progesterone and progestins: neuroprotection and myelin repair", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 8, no. 6, 1 December 2008 (2008-12-01), pages 740 - 746, XP025669940, ISSN: 1471-4892, [retrieved on 20081106], DOI: DOI:10.1016/J.COPH.2008.10.002 *

Also Published As

Publication number Publication date
EP2490680A2 (fr) 2012-08-29
WO2011049948A2 (fr) 2011-04-28
MX347890B (es) 2017-05-18
AU2010308308A1 (en) 2012-06-07
ES2669694T3 (es) 2018-05-28
MX2012004542A (es) 2012-11-29
US10052335B2 (en) 2018-08-21
CA2777551C (fr) 2015-12-22
JP2013508379A (ja) 2013-03-07
EP2490680B1 (fr) 2018-04-04
CA2777551A1 (fr) 2011-04-28
JP5871807B2 (ja) 2016-03-01
BR112012009306A2 (pt) 2016-06-07
US20120231052A1 (en) 2012-09-13
WO2011049948A4 (fr) 2011-08-04
AU2010308308B2 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
WO2011049948A3 (fr) Neuroprotection et réparation de la myéline au moyen de la nestorone®
WO2010088409A3 (fr) Procédés de neuroprotection utilisant des stéroïdes neuroprotecteurs et une vitamine d
WO2013078422A3 (fr) Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
NZ595790A (en) Method for on-demand contraception
WO2008021368A3 (fr) Compositions et méthodes de neuroprotection
MX363536B (es) Gel transdermico de progestina/estradiol.
WO2007144152A3 (fr) Schéma posologique prolongé et décroissant d'œstrogène
EP2097437A4 (fr) Utilisation de stéroïdes dérivés du prégnane et de l'androstane pour la fabrication d'une composition pharmaceutique pour le traitement de troubles du snc
WO2010081032A3 (fr) Compositions stéroïdiennes
WO2009009688A9 (fr) Système d'administration
PT2061561E (pt) Composições para tratar o cancro
IL207182A (en) Use of 17 alpha-acetoxy-11 beta- (4– n, n– dimethylamino phenyl) –19 – norfergana – 4, 9 – dian – 3, 20 – deion (Olipristal acetate) for the preparation of a drug to lower or stop bleeding in patients suffering from uterine fibroids
WO2011059969A3 (fr) Métabolites de stéroïdes de mammifères
IL204629A0 (en) Use of glycerol, method of crop treatment, composition for tank mixing and a method of preparation of a composition for tank mixing
EP2206502A4 (fr) Conjugué polymère-stéroïde
AU2009256009A8 (en) Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
ZA200700483B (en) Process for the preparation 2-substituted-derivatives of estrone and estradiol
HK1131396A1 (en) 11-phosphorous steroid derivatives useful as progesterone receptor modulators
HK1148704A1 (zh) 用於治療性應用的 甾族化合物
PL2120976T3 (pl) Sposoby leczenia nietrzymania odbytowego z użyciem mioblastów
WO2009089399A3 (fr) Compositions comprenant des antagonistes du récepteur ou du co-récepteur de type toll et procédés de neuroprotection oculaire
HK1144287A1 (en) Steroids derivatives as selective progesterone receptor modulators
WO2012129365A4 (fr) Rénégération de myéline par des androgènes
EP2124722A4 (fr) Traitement par pression combinée pour traiter les taux de lipides sériques, les niveaux de stéroïdes et la stéroïdogenèse
IL202205A (en) Process for the preparation of steroids converted at position 17α by 3-hydroxypropyl and at position 17ß - by hydroxy from the corresponding 14-oxo history and intermediates obtained in this process

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10768168

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2777551

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/004542

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012535303

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010768168

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010308308

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 13500008

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2010308308

Country of ref document: AU

Date of ref document: 20101019

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012009306

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012009306

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120419